BRAF Mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer
Early Detection of Cancer
Proto-Oncogene Proteins B-raf
V600E BRAF mutations were present in 35% of patients who had SB/LGS ovarian cancers. The presence of the BRAF V600E mutation in SB/LGS ovarian cancer was associated with early stage disease and improved prognosis. The authors concluded that patients with SB/LGS ovarian cancer who require systemic therapy are unlikely to have BRAF mutant tumors.